Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 3
2(40.0%)
Phase 4
1(20.0%)
5Total
Phase 2(2)
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07303283Phase 2Not Yet Recruiting

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

Role: collaborator

NCT07353749Phase 4Not Yet Recruiting

Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms

Role: collaborator

NCT05340270Phase 2Active Not Recruiting

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT02434614Phase 3Unknown

Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT01479504Phase 3Unknown

A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Role: collaborator

All 5 trials loaded